Morgan Stanley Maintains Overweight on Monopar Therapeutics, Raises Price Target to $133
Benzinga Newsdesk 19 hours ago
Analyst RatingsNewsPrice Target
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Morgan Stanley analyst Maxwell Skor maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $130 to $133.
Morgan Stanley analyst Maxwell Skor maintains Monopar Therapeutics (NASDAQ:MNPR) with a Overweight and raises the price target from $130 to $133.
